continuous glucose monitoring (cgm) system with share Search Results


continuous glucose monitoring (cgm) system with share  (Dexcom Inc)
90
Dexcom Inc continuous glucose monitoring (cgm) system with share
Summary of commercially available mobile medical apps for DM management (N = 14)
Continuous Glucose Monitoring (Cgm) System With Share, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring (cgm) system with share/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitoring (cgm) system with share - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitor (cgm) device  (Meiqi Trading Co)
90
Meiqi Trading Co continuous glucose monitor (cgm) device
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitor (Cgm) Device, supplied by Meiqi Trading Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitor (cgm) device/product/Meiqi Trading Co
Average 90 stars, based on 1 article reviews
continuous glucose monitor (cgm) device - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
novel intravenous continuous glucose monitoring (cgm) system (glucoclear™;  (Edwards Lifesciences Inc)
90
Edwards Lifesciences Inc novel intravenous continuous glucose monitoring (cgm) system (glucoclear™;
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Novel Intravenous Continuous Glucose Monitoring (Cgm) System (Glucoclear™;, supplied by Edwards Lifesciences Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/novel intravenous continuous glucose monitoring (cgm) system (glucoclear™;/product/Edwards Lifesciences Inc
Average 90 stars, based on 1 article reviews
novel intravenous continuous glucose monitoring (cgm) system (glucoclear™; - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitor data dexcom clarity  (Dexcom Inc)
90
Dexcom Inc continuous glucose monitor data dexcom clarity
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitor Data Dexcom Clarity, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitor data dexcom clarity/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitor data dexcom clarity - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
minimally invasive continuous glucose monitoring (cgm) systems  (MiniMed Inc)
90
MiniMed Inc minimally invasive continuous glucose monitoring (cgm) systems
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Minimally Invasive Continuous Glucose Monitoring (Cgm) Systems, supplied by MiniMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minimally invasive continuous glucose monitoring (cgm) systems/product/MiniMed Inc
Average 90 stars, based on 1 article reviews
minimally invasive continuous glucose monitoring (cgm) systems - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitors (cgm)  (TaiDoc Technology)
90
TaiDoc Technology continuous glucose monitors (cgm)
(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor <t>(CGM)</t> data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients <t>by</t> <t>WMT.</t> Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.
Continuous Glucose Monitors (Cgm), supplied by TaiDoc Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitors (cgm)/product/TaiDoc Technology
Average 90 stars, based on 1 article reviews
continuous glucose monitors (cgm) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitoring (cgm)  (RStudio)
90
RStudio continuous glucose monitoring (cgm)
The framework diagram illustrates the comprehensive screening methodology employed in the evaluation of research literature pertinent to the clinical practice of Continuous Glucose Monitoring <t>(CGM)</t> <t>in</t> <t>Diabetes</t> Mellitus from 2012-2022.
Continuous Glucose Monitoring (Cgm), supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring (cgm)/product/RStudio
Average 90 stars, based on 1 article reviews
continuous glucose monitoring (cgm) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dex) continuous glucose monitoring (cgm) device  (Dexcom Inc)
90
Dexcom Inc dex) continuous glucose monitoring (cgm) device
Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.
Dex) Continuous Glucose Monitoring (Cgm) Device, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dex) continuous glucose monitoring (cgm) device/product/Dexcom Inc
Average 90 stars, based on 1 article reviews
dex) continuous glucose monitoring (cgm) device - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitoring cgm  (CompuGroup)
90
CompuGroup continuous glucose monitoring cgm
Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.
Continuous Glucose Monitoring Cgm, supplied by CompuGroup, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring cgm/product/CompuGroup
Average 90 stars, based on 1 article reviews
continuous glucose monitoring cgm - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitoring (cgm) devices  (Eli Lilly)
90
Eli Lilly continuous glucose monitoring (cgm) devices
Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.
Continuous Glucose Monitoring (Cgm) Devices, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring (cgm) devices/product/Eli Lilly
Average 90 stars, based on 1 article reviews
continuous glucose monitoring (cgm) devices - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
continuous glucose monitoring (cgm) und sensor-augmented pump therapy (sap)  (Unimed Inc)
90
Unimed Inc continuous glucose monitoring (cgm) und sensor-augmented pump therapy (sap)
Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.
Continuous Glucose Monitoring (Cgm) Und Sensor Augmented Pump Therapy (Sap), supplied by Unimed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous glucose monitoring (cgm) und sensor-augmented pump therapy (sap)/product/Unimed Inc
Average 90 stars, based on 1 article reviews
continuous glucose monitoring (cgm) und sensor-augmented pump therapy (sap) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cgm continuous glucose monitor  (Clinical and Laboratory Standards Institute)
90
Clinical and Laboratory Standards Institute cgm continuous glucose monitor
Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.
Cgm Continuous Glucose Monitor, supplied by Clinical and Laboratory Standards Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cgm continuous glucose monitor/product/Clinical and Laboratory Standards Institute
Average 90 stars, based on 1 article reviews
cgm continuous glucose monitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Summary of commercially available mobile medical apps for DM management (N = 14)

Journal: Endocrinology and metabolism clinics of North America

Article Title: Evidence-based Mobile Medical Applications in Diabetes

doi: 10.1016/j.ecl.2016.06.001

Figure Lengend Snippet: Summary of commercially available mobile medical apps for DM management (N = 14)

Article Snippet: 9 Share (Dexcom) Dexcom continuous glucose monitoring (CGM) system with Share is an FDA-approved CGM system with Bluetooth technology built into the receiver that allows uploading of real-time CGM data via an iOS device onto a Health Insurance Portability and Accountability Act (HIPAA)–compliant server that can be shared with family and the care team.

Techniques: Activity Assay, Selection, Software, Medications

(A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor (CGM) data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients by WMT. Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.

Journal: Journal of Diabetes

Article Title: Washed microbiota transplantation reduces glycemic variability in unstable diabetes

doi: 10.1111/1753-0407.13485

Figure Lengend Snippet: (A) Flow diagram of study design and participating patients. (B) Changes of daily insulin dose. Data of the same subject at different follow‐up time points are connected by gray lines. False discovery rate (represented as q ‐value) was calculated using repeated‐measures one‐way analysis of variance corrected by Benjamini and Hochberg method for multiple comparisons, n = 14. (C) Postprandial glucose excursions expressed as percentage of baseline during steamed bun meal test (SBMT). All data are represented as mean ± SEM, * q < 0.05 by mixed‐effects model for repeated measures corrected by Benjamini and Hochberg method, n = 9–12. (D–H) Changes of glycemic variability (GV) indices at 1 week (T1W) calculated using continuous glucose monitor (CGM) data: (D) MAGE, (E) SDBG, (F) BG > 11.1 mmol/L, (G) LAGE, and (H) MBG. † p < .05 by paired t test (two‐tailed), n = 14. (I–J) Changes of GV indices at T1W, 1 month (T1M), and 3 months (T3M) calculated using self‐monitoring of blood glucose data: (I) TIR and (J) hypoglycemic episodes. $ q < 0.05 as stated in (B); # q < 0.05 by repeated‐measures Friedman test corrected by Benjamini and Hochberg method, n = 14. (K) Representative CGM 24‐h glucose profiles demonstrating improved glycemic stability in two patients by WMT. Values of some GV indices were the same for different participants. Thus, both points and connecting lines overlapped with each other, exhibiting fewer than 14 points. LAGE, largest amplitude of glycemic excursions; MAGE, mean amplitude of glycemic excursion; MBG, mean blood glucose; SDBG, SD of blood glucose; TIR, time in range; WMT, washed microbiota transplantation.

Article Snippet: Three days before WMT, patients were implanted with a continuous glucose monitor (CGM) device (MeiQi Medical Instruments Co., Ltd., Huzhou, China).

Techniques: Two Tailed Test, Transplantation Assay

Washed microbiota transplantation (WMT) alters profiles of serum metabolites. (A) Heatmap showing changes of serum metabolites determined by non‐targeted metabolomics, n = 11–14. (B) Heatmap of Spearman's correlation coefficients between serum metabolites and glycemic variability (GV) indices. (C) The 8 positively correlated metabolites between fecal and serum compartments. Color range varies from light red (weaker correlation) to dark red (stronger correlation). Statistical methods were the same as stated in Figure . AUC, area under the curve; BG, blood glucose; CGM, continuous glucose monitor; CV, coefficient of variation; HbA1c, glycated hemoglobin; LAGE, largest amplitude of glycemic excursions; MBG, mean blood glucose; PPGE, postprandial glucose excursion; SBMT, steamed bun meal test; SMBG, self‐monitoring of blood glucose; TIR, time in range.

Journal: Journal of Diabetes

Article Title: Washed microbiota transplantation reduces glycemic variability in unstable diabetes

doi: 10.1111/1753-0407.13485

Figure Lengend Snippet: Washed microbiota transplantation (WMT) alters profiles of serum metabolites. (A) Heatmap showing changes of serum metabolites determined by non‐targeted metabolomics, n = 11–14. (B) Heatmap of Spearman's correlation coefficients between serum metabolites and glycemic variability (GV) indices. (C) The 8 positively correlated metabolites between fecal and serum compartments. Color range varies from light red (weaker correlation) to dark red (stronger correlation). Statistical methods were the same as stated in Figure . AUC, area under the curve; BG, blood glucose; CGM, continuous glucose monitor; CV, coefficient of variation; HbA1c, glycated hemoglobin; LAGE, largest amplitude of glycemic excursions; MBG, mean blood glucose; PPGE, postprandial glucose excursion; SBMT, steamed bun meal test; SMBG, self‐monitoring of blood glucose; TIR, time in range.

Article Snippet: Three days before WMT, patients were implanted with a continuous glucose monitor (CGM) device (MeiQi Medical Instruments Co., Ltd., Huzhou, China).

Techniques: Transplantation Assay

The framework diagram illustrates the comprehensive screening methodology employed in the evaluation of research literature pertinent to the clinical practice of Continuous Glucose Monitoring (CGM) in Diabetes Mellitus from 2012-2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The framework diagram illustrates the comprehensive screening methodology employed in the evaluation of research literature pertinent to the clinical practice of Continuous Glucose Monitoring (CGM) in Diabetes Mellitus from 2012-2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

Trends in the Number of Publications on the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: Trends in the Number of Publications on the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

(A) An Analysis of International Cooperation Between Diverse Countries. The correlation among distinct color blocks signifies the bilateral collaborative association between the two countries. (B) Cooperation of Countries or Regions that Contributed to Publications on the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022. The size of the purple ring area serves as an indicator of the scope of influence of the regional articles and is equivalent to their centrality.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: (A) An Analysis of International Cooperation Between Diverse Countries. The correlation among distinct color blocks signifies the bilateral collaborative association between the two countries. (B) Cooperation of Countries or Regions that Contributed to Publications on the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022. The size of the purple ring area serves as an indicator of the scope of influence of the regional articles and is equivalent to their centrality.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

Top 10 countries or regions with publications on clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: Top 10 countries or regions with publications on clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

The top 10 institutions with publications on clinical practice of CGM in diabetes mellitus from 2012-2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The top 10 institutions with publications on clinical practice of CGM in diabetes mellitus from 2012-2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

(A) Collaborative Network Analysis by CiteSpace Amongst Institutions Pertaining to the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022. Each node with colorful annual rings represents an institution, and the size of each node represents its relative quantity of research output. (B) The overlay visualization map of Institution co-authorship analysis conducted by VOSviewer.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: (A) Collaborative Network Analysis by CiteSpace Amongst Institutions Pertaining to the Clinical Practice of CGM in Diabetes Mellitus from 2012 to 2022. Each node with colorful annual rings represents an institution, and the size of each node represents its relative quantity of research output. (B) The overlay visualization map of Institution co-authorship analysis conducted by VOSviewer.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

The Top 10 citing and cited journals of publications on the clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The Top 10 citing and cited journals of publications on the clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

The Dual-map Overlay of Journals on the Clinical Practice of CGM in Diabetes Mellitus. The green path at the top suggests that research literature from MEDICINE, MEDICAL, CLINICAL area may be utilized to support the results and findings in the field of MOLECULES, BIOLOGY, GENETICS research. The findings from research literature in the MEDCINE, MEDICAL, CLINICAL area may be utilized to support the results from research conducted in the HEALTH, NURSING, MEDICINE area.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The Dual-map Overlay of Journals on the Clinical Practice of CGM in Diabetes Mellitus. The green path at the top suggests that research literature from MEDICINE, MEDICAL, CLINICAL area may be utilized to support the results and findings in the field of MOLECULES, BIOLOGY, GENETICS research. The findings from research literature in the MEDCINE, MEDICAL, CLINICAL area may be utilized to support the results from research conducted in the HEALTH, NURSING, MEDICINE area.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

(A) Co-occurrence Keywords Network and Density Visualization on the Clinical Practice of CGM in Diabetes Mellitus from 2012-2022. (B) CiteSpace visualization timeline view of keywords clustering analysis related to the clinical practice of CGM in diabetes.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: (A) Co-occurrence Keywords Network and Density Visualization on the Clinical Practice of CGM in Diabetes Mellitus from 2012-2022. (B) CiteSpace visualization timeline view of keywords clustering analysis related to the clinical practice of CGM in diabetes.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

Top 10 keywords related to the clinical practice of CGM in diabetes mellitus from 2012-2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: Top 10 keywords related to the clinical practice of CGM in diabetes mellitus from 2012-2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques: Control

Keywords with the Strongest Citation Bursts for Publications on the Clinical Practice of CGM in Diabetes Mellitus Diabetic from 2012- 2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: Keywords with the Strongest Citation Bursts for Publications on the Clinical Practice of CGM in Diabetes Mellitus Diabetic from 2012- 2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

The Timeline View of Keyword Clustering Analysis Related to the Clinical Practice of CGM in Diabetes Mellitus was Visualized Using CiteSpace. The clusters formed by the keywords were represented by different colored horizontal lines, with labels on the right. The nodes positioned on these horizontal lines depicted the keywords themselves, while the position of the nodes on the horizontal lines indicated the year of the literature in which the keywords first appeared, thus forming a timeline representing the evolution of the keyword clusters.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The Timeline View of Keyword Clustering Analysis Related to the Clinical Practice of CGM in Diabetes Mellitus was Visualized Using CiteSpace. The clusters formed by the keywords were represented by different colored horizontal lines, with labels on the right. The nodes positioned on these horizontal lines depicted the keywords themselves, while the position of the nodes on the horizontal lines indicated the year of the literature in which the keywords first appeared, thus forming a timeline representing the evolution of the keyword clusters.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques:

The Top 10 references of publications on the clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Journal: Frontiers in Endocrinology

Article Title: A systematic bibliometric analysis on the clinical practice of CGM in diabetes mellitus from 2012 to 2022

doi: 10.3389/fendo.2023.1229494

Figure Lengend Snippet: The Top 10 references of publications on the clinical practice of CGM in diabetes mellitus from 2012 to 2022.

Article Snippet: In this review, a comprehensive analysis of 3024 literature sources was conducted, and the resulting search data was used to plot the trends in studies related to the application of continuous glucose monitoring (CGM) to clinical practice in diabetes using R studio.

Techniques: Control, Biomarker Discovery, Clinical Proteomics

Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.

Journal: American Journal of Medicine Open

Article Title: Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes

doi: 10.1016/j.ajmo.2022.100008

Figure Lengend Snippet: Cohort 1: T1D Population. IBM MarketScan Research Databases, 2017-2019.

Article Snippet: We compared clinical outcomes after acquiring a FreeStyle Libre© Flash Continuous Glucose Monitoring System (FSL) or Dexcom (DEX) continuous glucose monitoring (CGM) device in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) treated with intensive insulin therapy.

Techniques:

Cohort 1: T2D participants. IBM MarketScan Research Databases, 2017-2019.

Journal: American Journal of Medicine Open

Article Title: Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes

doi: 10.1016/j.ajmo.2022.100008

Figure Lengend Snippet: Cohort 1: T2D participants. IBM MarketScan Research Databases, 2017-2019.

Article Snippet: We compared clinical outcomes after acquiring a FreeStyle Libre© Flash Continuous Glucose Monitoring System (FSL) or Dexcom (DEX) continuous glucose monitoring (CGM) device in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) treated with intensive insulin therapy.

Techniques: